The effects of vitamin D and parathyroid hormone (PTH) levels on incident fracture remain uncertain. To test the hypothesis that increasing serum 25-hydroxyvitamin D [25(OH)D] and decreasing PTH levels are associated with decreased risk of hip and any nonspine fracture, we conducted a prospective cohort study among 2614 community-dwelling white and black participants, aged ≥70 years, from the Health, Aging and Body Composition (Health ABC) Study. Serum and plasma samples were drawn at year 2, which formed the baseline for this analysis. Serum 25(OH)D and intact PTH (1-84) were measured using radioimmunoassay with DiaSorin reagents and EDTA plasma with a two-site immunoradiometric assay kit, respectively. Incident fractures (hip and any nonspine) were assessed after year 2, every 6 months, by self-report and validated by radiology reports. The median (interquartile range) follow-up times for hip and any nonspine fractures were 6.4 (6.1-6.5) and 6.4 (5.5-6.5) years, respectively. Cox proportional hazards regression was used to estimate the hazard ratios (HR) with 95% confidence intervals (CI) for fracture. There were 84 hip and 247 nonspine fractures that occurred over the follow-up period. The multivariable adjusted HRs (95% CIs) of hip fracture for participants in the lowest (≤17.78 ng/mL), second (17.79 to 24.36 ng/mL), and third quartiles (24.37 to 31.94 ng/mL) of 25(OH)D were 1.92 (0.97 to 3.83), 0.75 (0.32 to 1.72) and 1.86 (1.00 to 3.45), respectively, compared with participants in the highest 25(OH)D quartile (>31.94 ng/mL) (p trend = 0.217). Additional adjustment for IL-6 (p = 0.107), PTH (p = 0.124), and hip areal bone mineral density (p = 0.137) attenuated HRs of hip fracture in the lowest quartile by 16.3%, 17.4%, and 26.1%, respectively. There was no evidence of an association between 25(OH)D and any nonspine fractures, or between PTH and hip or any nonspine fractures. We found limited evidence to support an association between calciotropic hormones and hip and nonspine fractures in older men and women.
The effects of vitamin D and pan class="Gene">parathyroid hormone (PTH) levels on incident fracture remain uncertain. To test the hypothesis that increasing serum 25-hydroxyvitamin D [25(OH)D] and decreasing PTH levels are associated with decreased risk of hip and any nonspine fracture, we conducted a prospective cohort study among 2614 community-dwelling white and black participants, aged ≥70 years, from the Health, Aging and Body Composition (Health ABC) Study. Serum and plasma samples were drawn at year 2, which formed the baseline for this analysis. Serum 25(OH)D and intact PTH (1-84) were measured using radioimmunoassay with DiaSorin reagents and EDTA plasma with a two-site immunoradiometric assay kit, respectively. Incident fractures (hip and any nonspine) were assessed after year 2, every 6 months, by self-report and validated by radiology reports. The median (interquartile range) follow-up times for hip and any nonspine fractures were 6.4 (6.1-6.5) and 6.4 (5.5-6.5) years, respectively. Cox proportional hazards regression was used to estimate the hazard ratios (HR) with 95% confidence intervals (CI) for fracture. There were 84 hip and 247 nonspine fractures that occurred over the follow-up period. The multivariable adjusted HRs (95% CIs) of hip fracture for participants in the lowest (≤17.78 ng/mL), second (17.79 to 24.36 ng/mL), and third quartiles (24.37 to 31.94 ng/mL) of 25(OH)D were 1.92 (0.97 to 3.83), 0.75 (0.32 to 1.72) and 1.86 (1.00 to 3.45), respectively, compared with participants in the highest 25(OH)D quartile (>31.94 ng/mL) (p trend = 0.217). Additional adjustment for IL-6 (p = 0.107), PTH (p = 0.124), and hip areal bone mineral density (p = 0.137) attenuated HRs of hip fracture in the lowest quartile by 16.3%, 17.4%, and 26.1%, respectively. There was no evidence of an association between 25(OH)D and any nonspine fractures, or between PTH and hip or any nonspine fractures. We found limited evidence to support an association between calciotropic hormones and hip and nonspine fractures in older men and women.
Authors: N Binkley; D Krueger; C S Cowgill; L Plum; E Lake; K E Hansen; H F DeLuca; M K Drezner Journal: J Clin Endocrinol Metab Date: 2004-07 Impact factor: 5.958
Authors: Håkan Melhus; Greta Snellman; Rolf Gedeborg; Liisa Byberg; Lars Berglund; Hans Mallmin; Per Hellman; Rune Blomhoff; Emil Hagström; Johan Arnlöv; Karl Michaëlsson Journal: J Clin Endocrinol Metab Date: 2010-03-23 Impact factor: 5.958
Authors: Jugdeep K Dhesi; Stephen H D Jackson; Lindsay M Bearne; Caje Moniz; Michael V Hurley; Cameron G Swift; Theresa J Allain Journal: Age Ageing Date: 2004-11 Impact factor: 10.668
Authors: E M Simonsick; A B Newman; M C Nevitt; S B Kritchevsky; L Ferrucci; J M Guralnik; T Harris Journal: J Gerontol A Biol Sci Med Sci Date: 2001-10 Impact factor: 6.053
Authors: Lesley A Stevens; Josef Coresh; Christopher H Schmid; Harold I Feldman; Marc Froissart; John Kusek; Jerome Rossert; Frederick Van Lente; Robert D Bruce; Yaping Lucy Zhang; Tom Greene; Andrew S Levey Journal: Am J Kidney Dis Date: 2008-03 Impact factor: 8.860
Authors: Elizabeth A Platz; Michael F Leitzmann; Bruce W Hollis; Walter C Willett; Edward Giovannucci Journal: Cancer Causes Control Date: 2004-04 Impact factor: 2.506
Authors: Jane A Cauley; Andrea Z Lacroix; LieLing Wu; Mara Horwitz; Michelle E Danielson; Doug C Bauer; Jennifer S Lee; Rebecca D Jackson; John A Robbins; Chunyuan Wu; Frank Z Stanczyk; Meryl S LeBoff; Jean Wactawski-Wende; Gloria Sarto; Judith Ockene; Steven R Cummings Journal: Ann Intern Med Date: 2008-08-19 Impact factor: 25.391
Authors: Anne C Looker; Christine M Pfeiffer; David A Lacher; Rosemary L Schleicher; Mary Frances Picciano; Elizabeth A Yetley Journal: Am J Clin Nutr Date: 2008-12 Impact factor: 7.045
Authors: Jane A Cauley; Neeta Parimi; Kristine E Ensrud; Douglas C Bauer; Peggy M Cawthon; Steven R Cummings; Andrew R Hoffman; James M Shikany; Elizabeth Barrett-Connor; Eric Orwoll Journal: J Bone Miner Res Date: 2010-03 Impact factor: 6.741
Authors: M Osima; T T Borgen; M Lukic; G Grimnes; R M Joakimsen; E F Eriksen; Å Bjørnerem Journal: Osteoporos Int Date: 2017-11-14 Impact factor: 4.507
Authors: Jane A Cauley; Gail A Greendale; Kristine Ruppert; Yinjuan Lian; John F Randolph; Joan C Lo; Sherri-Ann Burnett-Bowie; Joel S Finkelstein Journal: J Clin Endocrinol Metab Date: 2015-02-26 Impact factor: 5.958
Authors: Kamil E Barbour; Li-Yung Lui; Kristine E Ensrud; Teresa A Hillier; Erin S LeBlanc; Steven W Ing; Marc C Hochberg; Jane A Cauley Journal: J Bone Miner Res Date: 2014-09 Impact factor: 6.741